Amir Vexler Named President and CEO of Orano USA

Vexler’s extensive international experience in the electric power industry includes manufacturing, engineering services, commercial operations, and business development.
Amir Vexler Orano USA CEOBETHESDA, Md., April 5, 2021 – Effective today, Amir Vexler has been appointed as the new President and CEO of Orano USA LLC, Orano’s operations in the United States providing commercial and federal customers with global expertise in nuclear materials management. Former CEO Sam Shakir is stepping down to pursue opportunities outside the company.

“I am delighted to welcome Amir into this position,” said Philippe Knoche, CEO of Orano Group. “Under Amir’s leadership, our U.S. operations will continue providing a strong opportunity for Orano to apply its global expertise and regional innovation in partnership with our customers to advance and manage nuclear energy’s life cycle performance as a powerful generator of low-carbon electricity and economic benefits.”

Vexler will also continue to serve as President of TN Americas, a position he has held since December 2019 when he joined Orano.

“Amir’s blend of international experience across multiple business operations brings additional strength to leading Orano USA’s unique portfolio of integrated business units, services, and commodities for the best interest of our clients, partners, and stakeholders in the U.S. region,” said Patrick Champalaune, Senior Executive Vice President Sales & Marketing for Orano Group.

Read Amir Vexler’s bio.

Headquartered in Bethesda, Maryland, Orano USA is a leading technology and services provider for decommissioning shutdown nuclear energy facilities, managing used nuclear fuel, conducting federal site clean-up and closure, and the sale of uranium, conversion, and enrichment services to the U.S. commercial and federal markets.

In the nuclear medicine field, Orano USA’s subsidiary Orano Med is developing a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells.

Image: © Orano, Amir Vexler, President and CEO, Orano USA
By clicking “I accept Cookies”, you agree with the cookies use to enhance site navigation, analyze site usage and compile statistics. To get more information, please read our Cookies Policy in the Legal Notice